Pharming Group NV - Asset Resilience Ratio
Pharming Group NV (PHAR) has an Asset Resilience Ratio of 24.07% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check PHAR strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2025)
This chart shows how Pharming Group NV's Asset Resilience Ratio has changed over time. See Pharming Group NV (PHAR) balance sheet quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Pharming Group NV's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Pharming Group NV stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $117.80 Million | 24.07% |
| Total Liquid Assets | $117.80 Million | 24.07% |
Asset Resilience Insights
- Good Liquidity Position: Pharming Group NV maintains a healthy 24.07% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Pharming Group NV Industry Peers by Asset Resilience Ratio
Compare Pharming Group NV's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC |
Biotechnology | -55.36% |
|
Krystal Biotech Inc
NASDAQ:KRYS |
Biotechnology | 23.06% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Pharming Group NV (2005–2025)
The table below shows the annual Asset Resilience Ratio data for Pharming Group NV.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 6.76% | $33.79 Million | $499.81 Million | -21.48pp |
| 2024-12-31 | 28.24% | $112.95 Million | $399.99 Million | -4.53pp |
| 2023-12-31 | 32.77% | $151.68 Million | $462.85 Million | -- |
| 2022-12-31 | 0.00% | $0.00 | $425.80 Million | -- |
| 2019-12-31 | -0.26% | $-661.91K | $255.91 Million | -5.84pp |
| 2008-12-31 | 5.59% | $5.22 Million | $93.40 Million | -11.30pp |
| 2005-12-31 | 16.88% | $6.92 Million | $40.96 Million | -- |
About Pharming Group NV
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE… Read more